BR112017014090A2 - composition, and, methods for producing a composition and stabilizing a nucleic acid molecule. - Google Patents

composition, and, methods for producing a composition and stabilizing a nucleic acid molecule.

Info

Publication number
BR112017014090A2
BR112017014090A2 BR112017014090-0A BR112017014090A BR112017014090A2 BR 112017014090 A2 BR112017014090 A2 BR 112017014090A2 BR 112017014090 A BR112017014090 A BR 112017014090A BR 112017014090 A2 BR112017014090 A2 BR 112017014090A2
Authority
BR
Brazil
Prior art keywords
composition
nucleic acid
acid molecule
stabilizing
producing
Prior art date
Application number
BR112017014090-0A
Other languages
Japanese (ja)
Portuguese (pt)
Inventor
Yamada Taimu
Toyofuku Hidekazu
Original Assignee
Bonac Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonac Corporation filed Critical Bonac Corporation
Publication of BR112017014090A2 publication Critical patent/BR112017014090A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Abstract

a presente invenção provê uma composição que compreende uma molécula de ácido nucleico e uma solução tampão, dita composição sendo distinguida pelo fato de que (a) a composição está na forma de uma solução a temperatura ambiente e (b) o teor da molécula de ácido nucleico em uma composição após uma composição ser armazenada a 25ºc e uma umidade relativa de 60% por 4 semanas é 80% ou mais relativa àquela em uma composição no tempo de iniciação do armazenamento.the present invention provides a composition comprising a nucleic acid molecule and a buffer solution, said composition being distinguished by the fact that (a) the composition is in the form of a solution at room temperature and (b) the content of the acid molecule nucleic acid in a composition after a composition is stored at 25ºC and a relative humidity of 60% for 4 weeks is 80% or more relative to that in a composition at the time of storage initiation.

BR112017014090-0A 2014-12-29 2015-10-30 composition, and, methods for producing a composition and stabilizing a nucleic acid molecule. BR112017014090A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2014-267087 2014-12-29
JP2014267087 2014-12-29
JP2015-081298 2015-04-10
JP2015081298 2015-04-10
PCT/JP2015/080849 WO2016108264A1 (en) 2014-12-29 2015-10-30 Composition containing nucleic acid molecule stably

Publications (1)

Publication Number Publication Date
BR112017014090A2 true BR112017014090A2 (en) 2018-03-06

Family

ID=56284418

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017014090-0A BR112017014090A2 (en) 2014-12-29 2015-10-30 composition, and, methods for producing a composition and stabilizing a nucleic acid molecule.

Country Status (14)

Country Link
US (2) US20180036409A1 (en)
EP (1) EP3241903A4 (en)
JP (2) JP6462723B2 (en)
KR (2) KR102585112B1 (en)
CN (1) CN107208094A (en)
AU (2) AU2015373071B2 (en)
BR (1) BR112017014090A2 (en)
CA (1) CA2971830A1 (en)
HK (1) HK1244030A1 (en)
IL (1) IL252905B (en)
MX (1) MX2017008730A (en)
RU (1) RU2723032C2 (en)
SG (1) SG11201705312PA (en)
WO (1) WO2016108264A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10751426B2 (en) 2015-10-30 2020-08-25 Bonac Corporation Composition stably containing single-stranded nucleic acid molecule that suppresses expression of TGF-β1 gene
CN110114076A (en) * 2016-10-27 2019-08-09 瑟莱塞尔 New ds oligonucleotides for treating cancer
FR3058061A1 (en) * 2016-10-27 2018-05-04 Selexel NEW USE OF DOUBLE STRAND OLIGONUCLEOTIDES
CN106857502A (en) * 2017-03-03 2017-06-20 湖北新纵科病毒疾病工程技术有限公司 A kind of the Sample storage liquid and store method that prevent RNA from degrading
WO2019022257A1 (en) 2017-07-28 2019-01-31 杏林製薬株式会社 Therapeutic agent for fibrosis
US20210188895A1 (en) 2017-10-13 2021-06-24 Bonac Corporation Single-stranded nucleic acid molecule, and production method therefor
CN109402127B (en) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 Group of high-affinity nucleic acid aptamers capable of being specifically bound with connective tissue growth factor and application of high-affinity nucleic acid aptamers

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58102724A (en) 1981-12-15 1983-06-18 Mitsubishi Chem Ind Ltd Slip resistant polyolefin molded product
DK0544713T3 (en) 1990-08-16 1997-09-29 Isis Pharmaceuticals Inc Oligonucleutides for modulating the effects of cytomegalovirus infections
AU727306B2 (en) * 1996-04-26 2000-12-07 Merck Sharp & Dohme Corp. DNA vaccine formulations
IL129497A0 (en) 1996-10-25 2000-02-29 Nexstar Pharmaceuticals Inc Vascular endothelial growth factor (vegf) nucleic acid ligand complexes
ZA99493B (en) * 1998-01-30 1999-07-22 Akzo Nobel Nv Method for the isolation of nucleic acid.
CN100471522C (en) * 1998-03-13 2009-03-25 惠氏 Polynucleotide compsn. method of prepn. and use thereof
DE19836559A1 (en) * 1998-08-12 2000-03-23 Antigen Gmbh Blood collection vessel
AU769771B2 (en) * 1999-12-02 2004-02-05 Hymo Corporation Polyacrylamide precast gels for electrophoresis, process for producing the same and electrophoresis method by using the gels
JP3967516B2 (en) * 2000-02-29 2007-08-29 ハイモ株式会社 DNA electrophoresis
DE10006662A1 (en) * 2000-02-15 2001-08-23 Antigen Produktions Gmbh Sample vessel for stabilizing and isolating nucleic acid, contains a lytic solution that stabilizes nucleic acid and a solid phase that binds it, especially for sampling whole blood
US20040058886A1 (en) * 2002-08-08 2004-03-25 Dharmacon, Inc. Short interfering RNAs having a hairpin structure containing a non-nucleotide loop
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
MXPA05013746A (en) * 2003-06-18 2006-06-27 Yissum Res Dev Co Sphingoid polyalkylamine conjugates for vaccination.
JP2007505613A (en) * 2003-09-17 2007-03-15 センテリオン Method for preparing pharmaceutical grade plasmid DNA
EA011554B1 (en) * 2004-09-17 2009-04-28 Сентелион Stable liquid formulations of plasmid dna
DE102005023170A1 (en) * 2005-05-19 2006-11-23 Curevac Gmbh Optimized formulation for mRNA
TW200808360A (en) * 2006-04-13 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
JP5749494B2 (en) * 2008-01-02 2015-07-15 テクミラ ファーマシューティカルズ コーポレイション Improved compositions and methods for delivery of nucleic acids
JP5608998B2 (en) * 2009-03-31 2014-10-22 東洋紡株式会社 Nucleic acid amplification detection reagent kit with excellent storage stability
US8691782B2 (en) * 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
AU2012207606B2 (en) * 2011-01-11 2017-02-23 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
LT2773326T (en) * 2011-11-04 2019-04-25 Nitto Denko Corporation Method for sterilely producing lipid-nucleic acid particles
US9717801B2 (en) * 2012-03-15 2017-08-01 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Glycogen-based cationic polymers
EP2846839B1 (en) * 2012-05-10 2019-02-20 Adynxx, Inc. Formulations for the delivery of active ingredients
US9820942B2 (en) * 2013-03-06 2017-11-21 Biomics Biotechnologies Co., Ltd. Lipidosome preparation, preparation method and application thereof

Also Published As

Publication number Publication date
US20240016937A1 (en) 2024-01-18
JP2019077696A (en) 2019-05-23
CN107208094A (en) 2017-09-26
WO2016108264A1 (en) 2016-07-07
AU2015373071B2 (en) 2022-03-31
MX2017008730A (en) 2017-11-17
KR20220035404A (en) 2022-03-22
KR20170094797A (en) 2017-08-21
KR102585112B1 (en) 2023-10-10
SG11201705312PA (en) 2017-07-28
EP3241903A4 (en) 2018-07-04
JPWO2016108264A1 (en) 2017-08-31
RU2017126568A (en) 2019-01-31
US20180036409A1 (en) 2018-02-08
IL252905A0 (en) 2017-08-31
RU2017126568A3 (en) 2019-05-20
AU2022204391A1 (en) 2022-07-14
CA2971830A1 (en) 2016-07-07
RU2723032C2 (en) 2020-06-08
HK1244030A1 (en) 2018-07-27
IL252905B (en) 2020-09-30
JP6462723B2 (en) 2019-01-30
JP6808710B2 (en) 2021-01-06
EP3241903A1 (en) 2017-11-08
AU2015373071A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
BR112017014090A2 (en) composition, and, methods for producing a composition and stabilizing a nucleic acid molecule.
BR112021024352A2 (en) Composition of nicotine sachet, oral nicotine sachet product, and method for making the oral nicotine sachet product
BR112017027567A2 (en) fusion proteins to inhibit angiogenesis
BR112016015496A2 (en) composition and process for the production of composition
CL2020000946A1 (en) Methods and compositions for the production of nucleoside triphosphate and ribonucleic acid
CL2019002244A1 (en) Variants of pertuzumab and their evaluation. (divisional request 201702445)
BR112017009258A2 (en) electronic steam supply system and cartomizer for the same
PE20171238A1 (en) STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR NUCLEIC ACIDS ADMINISTRATION
EA201691579A1 (en) DERIVATIVES OF SULFAMOILPYRROLAMIDE AND THEIR APPLICATION AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
EA201892123A1 (en) 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDIN-5-CARBOXAMIDE AS APJ AGONISTS
EA201891336A1 (en) Heteroarylhydroxypyrimidinones as agonists of the APJ receptor
UY36949A (en) 2,4-DIHIDROXI-NICOTINAMIDS AS APJ AGONISTS
BR112018067995A2 (en) ophthalmic composition
ECSP14030779A (en) NAMPT INHIBITORS
BR112018013504A2 (en) method for deacetylation of biopolymers
BR112017010445B8 (en) Production process of diazabicyclo-octane derivative crystals and stable lyophilized preparation
BR112017008680A2 (en) impact modified polyamide transparent polymer composition
UY36204A (en) INSOINDOLIN DERIVATIVES.
UY37017A (en) AZA-BENCIMIDAZOL INHIBITORS OF PAD4
BR112016008352A2 (en) process for the production of neodymium catalyzed polybutadienes (ndbr), rubber blends containing neodymium catalyzed polybutadienes (ndbr), and uses of rubber blends
BR112017004797A2 (en) film, process for the manufacture of a laminate, and laminate with a front glass layer.
BR112016002573A2 (en) Method for the preparation of whole-muscle meat products containing oil and reconstituted meat products
BR112017013084A2 (en) polyethylene compositions with improved optical properties
BR112017008553A2 (en) polypropylene extrusion process
BR112017022472A2 (en) method for increasing the percentage of fab-dsfv monomeric antibody multimeric species

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]